Business Context and Reporting Period
This Form 10-Q covers The Procter & Gamble Company for the quarterly period ended September 30, 2002. The company operates globally across five primary segments: Fabric & Home Care, Baby & Family Care, Beauty Care, Health Care, and Snacks & Beverages. Effective July 1, 2002, the company realigned its reporting segments, moving the feminine care business into Beauty Care and renaming the Food and Beverage segment to Snacks & Beverages.
Key Financial Metrics
| Metric | Q1 2003 (Sep 30, 2002) | Q1 2002 (Sep 30, 2001) |
|---|---|---|
| Net Sales | $10,796 million | $9,766 million |
| Operating Income | $2,179 million | $1,762 million |
| Net Earnings | $1,464 million | $1,104 million |
| Diluted EPS | $1.04 | $0.79 |
| Operating Cash Flow | $2,010 million | $1,329 million |
| Free Cash Flow | $1,730 million | $970 million |
| Cash and Equivalents (End) | $4,703 million | $2,893 million |
| Total Debt (Current + Long-Term) | $15,462 million | $14,932 million |
| Gross Margin | 49.2% | 47.7% |
| Operating Margin | 20.2% | 18.0% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% to $10.80 billion, driven by a 13% increase in unit volume. Excluding acquisitions and divestitures, volume grew 10%.
- Profitability: Net earnings rose 32% to $1.46 billion. Core net earnings (excluding restructuring charges) were $1.58 billion, up from $1.34 billion in the prior year.
- Restructuring Charges: The current quarter included a $113 million after-tax restructuring charge ($151 million pre-tax), compared to a $238 million after-tax charge in the prior year quarter.
- Segment Performance:
- Beauty Care: Sales up 27% and earnings up 23%, significantly boosted by the Clairol acquisition.
- Health Care: Sales up 20% and earnings up 40%, driven by pharmaceuticals (Actonel) and oral care (Crest Whitestrips).
- Fabric & Home Care: Sales up 9% and earnings up 22%.
- Cash Flow: Operating cash flow increased $681 million year-over-year. Free cash flow improved by $760 million due to earnings growth and reduced capital expenditures.
Guidance, Outlook, and Risks
- Outlook: Management anticipates capital spending rates will increase through the year but expects the fiscal year average to remain below 5% of sales.
- Competitive Risks: In the family care segment, aggressive competitive promotional spending has pressured shares, though management anticipates a reversal as pulp costs rise. In oral care, a competitive entry into the tooth whitening category prompted a ~30% price decline for Crest Whitestrips effective October 2002.
- Regulatory Timing: The expected FDA approval for Prilosec OTC has been delayed to Fall 2003, though management states this has no material impact on current fiscal year results.
- Restructuring: The company continues a multi-year restructuring program involving approximately 900 employee separations in the quarter, with charges related to manufacturing consolidations and asset write-downs.
- Geographic Risks: Continued softness in the global economy, particularly in Latin America, is noted as a factor impacting volume growth in certain regions.
Investor Verification Checklist
- Verify the impact of the Clairol acquisition on Beauty Care segment margins and future integration costs.
- Monitor the competitive pricing environment in the family care (diapers) and oral care (whitening) segments and its effect on future gross margins.
- Review the restructuring program progress, specifically the timeline for realizing cost savings versus ongoing separation and asset write-down charges.
- Assess the delay in Prilosec OTC approval and its potential long-term impact on the Health Care segment pipeline.
- Confirm the capital expenditure trajectory to ensure it remains aligned with the <5% of sales target despite anticipated increases.